Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis
The number of programmed cell death protein 1 (PD-1) inhibitors is gradually increasing; this study aimed to comprehensively and systematically evaluate the impact of PD-1 inhibitors as second-line therapy for terminal or metastatic esophageal cancer (EC) on patient survival and the occurrence of ad...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology 2022-08, Vol.2022, p.1-12 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Journal of oncology |
| container_volume | 2022 |
| creator | Wang, Yidan Yang, Qiuxing Liu, Jia Shen, Xiying Tai, Guomei Gu, Hongmei |
| description | The number of programmed cell death protein 1 (PD-1) inhibitors is gradually increasing; this study aimed to comprehensively and systematically evaluate the impact of PD-1 inhibitors as second-line therapy for terminal or metastatic esophageal cancer (EC) on patient survival and the occurrence of adverse events. Suitable randomized controlled trials (RCTs) were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Moreover, we searched for conference abstracts from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) to compare the comprehensive curative effects of PD-1 inhibitors or single-agent therapy in terminal or metastatic EC. The primary outcome indicators were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Treatment-related adverse events (TRAEs) were the secondary outcome indicators. We compared the previously mentioned indicators of the two treatment modalities using Stata software (version 12.0). We compared the long-term survival rates of both treatment groups and analyzed the possible factors affecting OS. We selected five RCTs with 2197 patients as study subjects. Compared with conventional single-agent chemotherapy, PD-1 inhibitors greatly improved the patients’ OS (HR = 0.77, 95% CI 0.70–0.85, P |
| doi_str_mv | 10.1155/2022/4033863 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9436578</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A716148004</galeid><sourcerecordid>A716148004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-756b0c2b77185e37f520979e7b158d87199f722529082a71eae9f9db88b00453</originalsourceid><addsrcrecordid>eNp9kk2P0zAQhiMEYpeFGz_AEhckCGsncWxzQIpC-ZCKQLR3y0kmiVeJ3bXdrvr7-GM424qvAyeP_D7zzoxmkuQ5wW8IofQ6w1l2XeA852X-ILkkJWcpLyh--Ed8kTzx_gbjssCifJxc5CWmgmN8mfyo7bxzMILx-gCo3jsVlmDV99AGZHu0VW6AoM2Avr1PCbIObZ3qdNDWqAltojBBWg1gAqpHmG0YwandEWmDNtBa06VrbQBtz9_9YgBu1kt2jL9AUD7Eoi1aebsb1QBRqJVpwb1FFdocfYD5Xv8OBw13SJnuPiutosXRa_80edSrycOz83uVbD-stvWndP314-e6WqdtQfOQMlo2uM0axginkLOeZlgwAawhlHecESF6lmU0E5hnihFQIHrRNZw3GEeHq-TdyXa3b2bo2jixU5PcOT0rd5RWafm3YvQoB3uQoshLyng0eHk2cPZ2Dz7IWfsWpkkZsHsvM4aFIHnsLqIv_kFv7N7FeU8UjX2X-W9qUBNIbXob67aLqawYKUkRV1xE6vWJap313kH_q2WC5XJCcjkheT6hiL864aM2nbrT_6d_And1xQc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2709597963</pqid></control><display><type>article</type><title>Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis</title><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wang, Yidan ; Yang, Qiuxing ; Liu, Jia ; Shen, Xiying ; Tai, Guomei ; Gu, Hongmei</creator><contributor>Cao, Dan ; Dan Cao</contributor><creatorcontrib>Wang, Yidan ; Yang, Qiuxing ; Liu, Jia ; Shen, Xiying ; Tai, Guomei ; Gu, Hongmei ; Cao, Dan ; Dan Cao</creatorcontrib><description>The number of programmed cell death protein 1 (PD-1) inhibitors is gradually increasing; this study aimed to comprehensively and systematically evaluate the impact of PD-1 inhibitors as second-line therapy for terminal or metastatic esophageal cancer (EC) on patient survival and the occurrence of adverse events. Suitable randomized controlled trials (RCTs) were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Moreover, we searched for conference abstracts from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) to compare the comprehensive curative effects of PD-1 inhibitors or single-agent therapy in terminal or metastatic EC. The primary outcome indicators were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Treatment-related adverse events (TRAEs) were the secondary outcome indicators. We compared the previously mentioned indicators of the two treatment modalities using Stata software (version 12.0). We compared the long-term survival rates of both treatment groups and analyzed the possible factors affecting OS. We selected five RCTs with 2197 patients as study subjects. Compared with conventional single-agent chemotherapy, PD-1 inhibitors greatly improved the patients’ OS (HR = 0.77, 95% CI 0.70–0.85, P<0.001), but PFS (HR = 0.93, 95% CI 0.77–1.12, P=0.431) and DCR (RR = 0.93, 95% CI 0.71–1.22, P=0.609) were not greatly improved. Moreover, PD-1 inhibitors improved ORR (RR = 1.83, 95% CI 1.16–2.89, P=0.009) and decreased TRAEs (RR = 0.76, 95% CI 0.61–0.95, P<0.001) and serious TRAEs (RR = 0.40, 95% CI 0.32–0.49, P<0.001). Further analysis demonstrated that OS was affected by age, sex, region, smoking history, and the number of organ and lymph node metastases. Compared with the traditional single chemotherapy drugs, PD-1 inhibitors can achieve higher OS and ORR, fewer and more serious TRAEs, and better efficacy and safety for second-line therapy of terminal or metastatic EC.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2022/4033863</identifier><identifier>PMID: 36059800</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Analysis ; Apoptosis ; Bias ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical medicine ; Clinical trials ; Complications and side effects ; Drugs ; Esophageal cancer ; Evidence-based medicine ; Immunotherapy ; Lymphocytes ; Medical prognosis ; Medical research ; Medicine, Experimental ; Meta-analysis ; Metastasis ; Oncology ; Review ; Systematic review</subject><ispartof>Journal of oncology, 2022-08, Vol.2022, p.1-12</ispartof><rights>Copyright © 2022 Yidan Wang et al.</rights><rights>COPYRIGHT 2022 John Wiley & Sons, Inc.</rights><rights>Copyright © 2022 Yidan Wang et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022 Yidan Wang et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-756b0c2b77185e37f520979e7b158d87199f722529082a71eae9f9db88b00453</citedby><cites>FETCH-LOGICAL-c453t-756b0c2b77185e37f520979e7b158d87199f722529082a71eae9f9db88b00453</cites><orcidid>0000-0001-7001-1790 ; 0000-0002-8572-5435</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436578/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436578/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids></links><search><contributor>Cao, Dan</contributor><contributor>Dan Cao</contributor><creatorcontrib>Wang, Yidan</creatorcontrib><creatorcontrib>Yang, Qiuxing</creatorcontrib><creatorcontrib>Liu, Jia</creatorcontrib><creatorcontrib>Shen, Xiying</creatorcontrib><creatorcontrib>Tai, Guomei</creatorcontrib><creatorcontrib>Gu, Hongmei</creatorcontrib><title>Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis</title><title>Journal of oncology</title><description>The number of programmed cell death protein 1 (PD-1) inhibitors is gradually increasing; this study aimed to comprehensively and systematically evaluate the impact of PD-1 inhibitors as second-line therapy for terminal or metastatic esophageal cancer (EC) on patient survival and the occurrence of adverse events. Suitable randomized controlled trials (RCTs) were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Moreover, we searched for conference abstracts from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) to compare the comprehensive curative effects of PD-1 inhibitors or single-agent therapy in terminal or metastatic EC. The primary outcome indicators were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Treatment-related adverse events (TRAEs) were the secondary outcome indicators. We compared the previously mentioned indicators of the two treatment modalities using Stata software (version 12.0). We compared the long-term survival rates of both treatment groups and analyzed the possible factors affecting OS. We selected five RCTs with 2197 patients as study subjects. Compared with conventional single-agent chemotherapy, PD-1 inhibitors greatly improved the patients’ OS (HR = 0.77, 95% CI 0.70–0.85, P<0.001), but PFS (HR = 0.93, 95% CI 0.77–1.12, P=0.431) and DCR (RR = 0.93, 95% CI 0.71–1.22, P=0.609) were not greatly improved. Moreover, PD-1 inhibitors improved ORR (RR = 1.83, 95% CI 1.16–2.89, P=0.009) and decreased TRAEs (RR = 0.76, 95% CI 0.61–0.95, P<0.001) and serious TRAEs (RR = 0.40, 95% CI 0.32–0.49, P<0.001). Further analysis demonstrated that OS was affected by age, sex, region, smoking history, and the number of organ and lymph node metastases. Compared with the traditional single chemotherapy drugs, PD-1 inhibitors can achieve higher OS and ORR, fewer and more serious TRAEs, and better efficacy and safety for second-line therapy of terminal or metastatic EC.</description><subject>Analysis</subject><subject>Apoptosis</subject><subject>Bias</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Complications and side effects</subject><subject>Drugs</subject><subject>Esophageal cancer</subject><subject>Evidence-based medicine</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Meta-analysis</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Review</subject><subject>Systematic review</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kk2P0zAQhiMEYpeFGz_AEhckCGsncWxzQIpC-ZCKQLR3y0kmiVeJ3bXdrvr7-GM424qvAyeP_D7zzoxmkuQ5wW8IofQ6w1l2XeA852X-ILkkJWcpLyh--Ed8kTzx_gbjssCifJxc5CWmgmN8mfyo7bxzMILx-gCo3jsVlmDV99AGZHu0VW6AoM2Avr1PCbIObZ3qdNDWqAltojBBWg1gAqpHmG0YwandEWmDNtBa06VrbQBtz9_9YgBu1kt2jL9AUD7Eoi1aebsb1QBRqJVpwb1FFdocfYD5Xv8OBw13SJnuPiutosXRa_80edSrycOz83uVbD-stvWndP314-e6WqdtQfOQMlo2uM0axginkLOeZlgwAawhlHecESF6lmU0E5hnihFQIHrRNZw3GEeHq-TdyXa3b2bo2jixU5PcOT0rd5RWafm3YvQoB3uQoshLyng0eHk2cPZ2Dz7IWfsWpkkZsHsvM4aFIHnsLqIv_kFv7N7FeU8UjX2X-W9qUBNIbXob67aLqawYKUkRV1xE6vWJap313kH_q2WC5XJCcjkheT6hiL864aM2nbrT_6d_And1xQc</recordid><startdate>20220825</startdate><enddate>20220825</enddate><creator>Wang, Yidan</creator><creator>Yang, Qiuxing</creator><creator>Liu, Jia</creator><creator>Shen, Xiying</creator><creator>Tai, Guomei</creator><creator>Gu, Hongmei</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7001-1790</orcidid><orcidid>https://orcid.org/0000-0002-8572-5435</orcidid></search><sort><creationdate>20220825</creationdate><title>Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis</title><author>Wang, Yidan ; Yang, Qiuxing ; Liu, Jia ; Shen, Xiying ; Tai, Guomei ; Gu, Hongmei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-756b0c2b77185e37f520979e7b158d87199f722529082a71eae9f9db88b00453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Apoptosis</topic><topic>Bias</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Complications and side effects</topic><topic>Drugs</topic><topic>Esophageal cancer</topic><topic>Evidence-based medicine</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Meta-analysis</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Review</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yidan</creatorcontrib><creatorcontrib>Yang, Qiuxing</creatorcontrib><creatorcontrib>Liu, Jia</creatorcontrib><creatorcontrib>Shen, Xiying</creatorcontrib><creatorcontrib>Tai, Guomei</creatorcontrib><creatorcontrib>Gu, Hongmei</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yidan</au><au>Yang, Qiuxing</au><au>Liu, Jia</au><au>Shen, Xiying</au><au>Tai, Guomei</au><au>Gu, Hongmei</au><au>Cao, Dan</au><au>Dan Cao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis</atitle><jtitle>Journal of oncology</jtitle><date>2022-08-25</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>The number of programmed cell death protein 1 (PD-1) inhibitors is gradually increasing; this study aimed to comprehensively and systematically evaluate the impact of PD-1 inhibitors as second-line therapy for terminal or metastatic esophageal cancer (EC) on patient survival and the occurrence of adverse events. Suitable randomized controlled trials (RCTs) were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Moreover, we searched for conference abstracts from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) to compare the comprehensive curative effects of PD-1 inhibitors or single-agent therapy in terminal or metastatic EC. The primary outcome indicators were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Treatment-related adverse events (TRAEs) were the secondary outcome indicators. We compared the previously mentioned indicators of the two treatment modalities using Stata software (version 12.0). We compared the long-term survival rates of both treatment groups and analyzed the possible factors affecting OS. We selected five RCTs with 2197 patients as study subjects. Compared with conventional single-agent chemotherapy, PD-1 inhibitors greatly improved the patients’ OS (HR = 0.77, 95% CI 0.70–0.85, P<0.001), but PFS (HR = 0.93, 95% CI 0.77–1.12, P=0.431) and DCR (RR = 0.93, 95% CI 0.71–1.22, P=0.609) were not greatly improved. Moreover, PD-1 inhibitors improved ORR (RR = 1.83, 95% CI 1.16–2.89, P=0.009) and decreased TRAEs (RR = 0.76, 95% CI 0.61–0.95, P<0.001) and serious TRAEs (RR = 0.40, 95% CI 0.32–0.49, P<0.001). Further analysis demonstrated that OS was affected by age, sex, region, smoking history, and the number of organ and lymph node metastases. Compared with the traditional single chemotherapy drugs, PD-1 inhibitors can achieve higher OS and ORR, fewer and more serious TRAEs, and better efficacy and safety for second-line therapy of terminal or metastatic EC.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>36059800</pmid><doi>10.1155/2022/4033863</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-7001-1790</orcidid><orcidid>https://orcid.org/0000-0002-8572-5435</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-8450 |
| ispartof | Journal of oncology, 2022-08, Vol.2022, p.1-12 |
| issn | 1687-8450 1687-8450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9436578 |
| source | PubMed Central Open Access; Wiley-Blackwell Open Access Titles; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Analysis Apoptosis Bias Cancer Cancer therapies Care and treatment Chemotherapy Clinical medicine Clinical trials Complications and side effects Drugs Esophageal cancer Evidence-based medicine Immunotherapy Lymphocytes Medical prognosis Medical research Medicine, Experimental Meta-analysis Metastasis Oncology Review Systematic review |
| title | Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A12%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comprehensive%20Curative%20Effect%20of%20Targeting%20PD-1%20or%20Traditional%20Single-Agent%20Chemotherapy%20in%20Second-Line%20Therapy%20for%20Terminal%20or%20Metastatic%20Esophageal%20Cancer:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Journal%20of%20oncology&rft.au=Wang,%20Yidan&rft.date=2022-08-25&rft.volume=2022&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2022/4033863&rft_dat=%3Cgale_pubme%3EA716148004%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2709597963&rft_id=info:pmid/36059800&rft_galeid=A716148004&rfr_iscdi=true |